[{"id":"2a05375a-5452-4690-a731-769e2628d4de","acronym":"TRANSCEND-CLL-004","url":"https://clinicaltrials.gov/study/NCT03331198","created_at":"2021-01-18T16:27:01.921Z","updated_at":"2024-07-02T16:34:59.670Z","phase":"Phase 1/2","brief_title":"Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","source_id_and_acronym":"NCT03331198 - TRANSCEND-CLL-004","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","biomarkers":" PLCG2 • CD5","pipe":" | ","alterations":" CD19 positive • PLCG2 mutation","tags":["PLCG2 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • PLCG2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Breyanzi (lisocabtagene maraleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 209","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 11/26/2027","primary_completion_date":" 11/26/2027","study_txt":" Completion: 11/26/2027","study_completion_date":" 11/26/2027","last_update_posted":"2024-05-31"},{"id":"5f8dd8d2-9e5b-4c4f-8ae9-408f4e7a1873","acronym":"","url":"https://clinicaltrials.gov/study/NCT03743246","created_at":"2021-01-18T18:20:05.034Z","updated_at":"2024-07-02T16:35:08.424Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)","source_id_and_acronym":"NCT03743246","lead_sponsor":"Celgene","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 10/17/2018","start_date":" 10/17/2018","primary_txt":" Primary completion: 01/26/2024","primary_completion_date":" 01/26/2024","study_txt":" Completion: 01/26/2024","study_completion_date":" 01/26/2024","last_update_posted":"2024-04-22"},{"id":"7be4ab54-ddca-4a37-9130-585a8186c64f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05583149","created_at":"2022-10-17T13:56:07.765Z","updated_at":"2025-02-25T15:00:41.267Z","phase":"Phase 2","brief_title":"Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas","source_id_and_acronym":"NCT05583149","lead_sponsor":"Patrick C. Johnson, MD","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Calquence (acalabrutinib) • Breyanzi (lisocabtagene maraleucel) • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-04-04"},{"id":"fe939754-1cac-4f5a-b6b4-bf23ef9b33d0","acronym":"PLATFORM","url":"https://clinicaltrials.gov/study/NCT03310619","created_at":"2021-01-18T16:21:00.823Z","updated_at":"2024-07-02T16:35:11.345Z","phase":"Phase 1/2","brief_title":"A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies","source_id_and_acronym":"NCT03310619 - PLATFORM","lead_sponsor":"Celgene","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imfinzi (durvalumab) • Imbruvica (ibrutinib) • Breyanzi (lisocabtagene maraleucel) • avadomide (CC-122) • iberdomide (CC-220) • relatlimab (BMS-986016) • golcadomide (CC-99282)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 12/20/2017","start_date":" 12/20/2017","primary_txt":" Primary completion: 02/15/2023","primary_completion_date":" 02/15/2023","study_txt":" Completion: 02/15/2023","study_completion_date":" 02/15/2023","last_update_posted":"2024-04-04"},{"id":"92a6a0af-b961-4dcd-9f55-a9a03ecbdb52","acronym":"TRANSCEND-NHL-001","url":"https://clinicaltrials.gov/study/NCT02631044","created_at":"2021-01-17T17:40:23.377Z","updated_at":"2024-07-02T16:35:12.562Z","phase":"Phase 1","brief_title":"Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)","source_id_and_acronym":"NCT02631044 - TRANSCEND-NHL-001","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" CD19 positive • Chr t(11;14) • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14) • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Breyanzi (lisocabtagene maraleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 387","initiation":"Initiation: 01/06/2016","start_date":" 01/06/2016","primary_txt":" Primary completion: 05/10/2024","primary_completion_date":" 05/10/2024","study_txt":" Completion: 05/10/2024","study_completion_date":" 05/10/2024","last_update_posted":"2024-03-27"},{"id":"81d99580-964a-4d43-9dfd-629d1f93a58c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03642626","created_at":"2021-01-18T17:52:54.288Z","updated_at":"2024-07-02T16:35:14.310Z","phase":"","brief_title":"MT2017-45: CAR-T Cell Therapy for Heme Malignancies","source_id_and_acronym":"NCT03642626","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Abecma (idecabtagene vicleucel) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 12/18/2018","start_date":" 12/18/2018","primary_txt":" Primary completion: 02/09/2024","primary_completion_date":" 02/09/2024","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-03-18"},{"id":"453e9d9e-7fd2-4c50-9add-8dcae3118995","acronym":"NCI-2022-02316","url":"https://clinicaltrials.gov/study/NCT05359211","created_at":"2022-05-03T14:54:08.402Z","updated_at":"2024-07-02T16:35:20.758Z","phase":"Phase 1","brief_title":"NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","source_id_and_acronym":"NCT05359211 - NCI-2022-02316","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV • avipendekin pegol (NKTR-255)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/08/2022","start_date":" 12/08/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-06"},{"id":"e600b098-b6d6-4213-a01e-a6f93ed80208","acronym":"TRANSCENDWORLD","url":"https://clinicaltrials.gov/study/NCT03484702","created_at":"2021-01-18T17:09:53.385Z","updated_at":"2024-07-02T16:35:23.640Z","phase":"Phase 2","brief_title":"Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03484702 - TRANSCENDWORLD","lead_sponsor":"Celgene","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Breyanzi (lisocabtagene maraleucel)"],"overall_status":"Completed","enrollment":" Enrollment 113","initiation":"Initiation: 09/07/2018","start_date":" 09/07/2018","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2024-01-12"},{"id":"3ab69e67-34d6-49bc-90c2-ca4e6baeb160","acronym":"TRANSCEND-PILOT-017006","url":"https://clinicaltrials.gov/study/NCT03483103","created_at":"2021-01-18T17:09:33.781Z","updated_at":"2024-07-02T16:35:25.636Z","phase":"Phase 2","brief_title":"Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)","source_id_and_acronym":"NCT03483103 - TRANSCEND-PILOT-017006","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Breyanzi (lisocabtagene maraleucel)"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 07/27/2018","start_date":" 07/27/2018","primary_txt":" Primary completion: 09/24/2021","primary_completion_date":" 09/24/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-12-20"},{"id":"07666392-68d5-4fad-ae36-30e09480e5ad","acronym":"OUTREACH","url":"https://clinicaltrials.gov/study/NCT03744676","created_at":"2021-01-18T18:20:28.707Z","updated_at":"2024-07-02T16:35:26.939Z","phase":"Phase 2","brief_title":"A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)","source_id_and_acronym":"NCT03744676 - OUTREACH","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD19 positive • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Breyanzi (lisocabtagene maraleucel)"],"overall_status":"Completed","enrollment":" Enrollment 104","initiation":"Initiation: 11/29/2018","start_date":" 11/29/2018","primary_txt":" Primary completion: 09/22/2023","primary_completion_date":" 09/22/2023","study_txt":" Completion: 09/22/2023","study_completion_date":" 09/22/2023","last_update_posted":"2023-12-06"},{"id":"f3c4514d-6e9f-4569-b66e-7499077a0fab","acronym":"TRANSFORM","url":"https://clinicaltrials.gov/study/NCT03575351","created_at":"2021-01-18T17:35:31.284Z","updated_at":"2024-07-02T16:35:29.075Z","phase":"Phase 3","brief_title":"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas","source_id_and_acronym":"NCT03575351 - TRANSFORM","lead_sponsor":"Celgene","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 184","initiation":"Initiation: 10/23/2018","start_date":" 10/23/2018","primary_txt":" Primary completion: 10/23/2023","primary_completion_date":" 10/23/2023","study_txt":" Completion: 10/23/2023","study_completion_date":" 10/23/2023","last_update_posted":"2023-11-15"}]